Sidley Austin and Moelis & Company have advised ARCHIMED. Goodwin Procter and Centerview Partners have advised Esperion Therapeutics. Akin Gump has advised Pharmakon Advisors. ARCHIMED, a...
ARCHIMED Acquires Esperion Therapeutics in $1.1 Billion Transaction
Prime Medicine Closes $144 Million Public Offering of Common Stock
Goodwin Procter, Foley Hoag, Honigman, and Wilson Sonsini Goodrich & Rosati have advised Prime Medicine Inc. on the offering, and Paul Hastings has advised the underwriters....
Nimbus Therapeutics’ $210 Million Private Financing
Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
Brainstorm Cell Therapeutics’ $7.5 Million Common Stock Direct Offering
Goodwin advised BrainStorm on the offering, and Ellenoff Grossman advised the placement agent. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced its registered direct offering of 4,054,055...
Nimbus Therapeutics’ $105 Million Private Financing Round
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
Cerevel Therapeutics’ $350 Million Public Offering
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
Aerpio Pharmaceuticals’ Merger with Aadi Bioscience
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
Aura Biosciences’ $80 Million Financing Round
Goodwin Procter LLP advised Aura Biosciences on the deal. Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital...